Molecular testing in CML between old and new methods: are we at a turning point?
S Soverini, S Bernardi, S Galimberti - Journal of clinical medicine, 2020 - mdpi.com
Molecular monitoring of minimal residual disease (MRD) and BCR-ABL1 kinase domain
(KD) mutation testing have a well consolidated role in the routine management of chronic …
(KD) mutation testing have a well consolidated role in the routine management of chronic …
Molecular monitoring in CML and the prospects for treatment-free remissions
MW Deininger - Hematology 2014, the American Society of …, 2015 - ashpublications.org
Monitoring treatment responses in chronic myeloid leukemia (CML) is based on complete
blood counts (CBCs) to determine hematologic response, karyotyping of bone marrow …
blood counts (CBCs) to determine hematologic response, karyotyping of bone marrow …
Present and future of molecular monitoring in chronic myeloid leukaemia
S Soverini, C De Benedittis, M Mancini… - British Journal of …, 2016 - Wiley Online Library
Currently, physicians treating chronic myeloid leukaemia (CML) patients can rely on a wide
spectrum of therapeutic options: the best use of such options is essential to achieve …
spectrum of therapeutic options: the best use of such options is essential to achieve …
Molecular monitoring in CML: how deep? How often? How should it influence therapy?
N Shanmuganathan, TP Hughes - Hematology 2014, the …, 2018 - ashpublications.org
With the advent of tyrosine kinase inhibitors (TKIs), the goals of therapy in chronic myeloid
leukemia (CML) are steadily shifting. Long-term disease control on TKI therapy has been the …
leukemia (CML) are steadily shifting. Long-term disease control on TKI therapy has been the …
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study
S Soverini, L Bavaro, C De Benedittis… - Blood, The Journal …, 2020 - ashpublications.org
In chronic myeloid leukemia (CML) patients, tyrosine kinase inhibitors (TKIs) may select for
drug-resistant BCR-ABL1 kinase domain (KD) mutants. Although Sanger sequencing (SS) is …
drug-resistant BCR-ABL1 kinase domain (KD) mutants. Although Sanger sequencing (SS) is …
Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper
S Soverini, E Abruzzese, M Bocchia… - Journal of hematology & …, 2019 - Springer
Abstract BCR-ABL1 kinase domain (KD) mutation status is considered to be an important
element of clinical decision algorithms for chronic myeloid leukemia (CML) patients who do …
element of clinical decision algorithms for chronic myeloid leukemia (CML) patients who do …
Current developments in molecular monitoring in chronic myeloid leukemia
JE Marum, S Branford - Therapeutic advances in …, 2016 - journals.sagepub.com
Molecular monitoring plays an essential role in the clinical management of chronic myeloid
leukemia (CML) patients, and now guides clinical decision making. Quantitative reverse …
leukemia (CML) patients, and now guides clinical decision making. Quantitative reverse …
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation
S Bernardi, M Malagola, C Zanaglio… - Cancer …, 2019 - Wiley Online Library
Abstract Treatment‐free remission (TFR) by tyrosine kinase inhibitors (TKI) discontinuation
in patients with deep molecular response (DMR) is a paramount goal in the current chronic …
in patients with deep molecular response (DMR) is a paramount goal in the current chronic …
Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA …
S Möbius, T Schenk, D Himsel, J Maier… - Journal of cancer …, 2019 - Springer
Purpose The advent of tyrosine kinase inhibitor (TKI) therapies has revolutionized the
treatment of chronic myeloid leukemia (CML). The European LeukemiaNet (ELN) …
treatment of chronic myeloid leukemia (CML). The European LeukemiaNet (ELN) …
Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia
NCP Cross, HE White, D Colomer, H Ehrencrona… - Leukemia, 2015 - nature.com
Abstract Treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors has
advanced to a stage where many patients achieve very low or undetectable levels of …
advanced to a stage where many patients achieve very low or undetectable levels of …